**Supplementary Material**

**Integrated DNA estimation in tissue biopsy and detection in liquid biopsy by HBV-targeted NGS assay**

Hsin-Ni Liu1, Selena Y. Lin2, Ricardo Ramirez3, Shin-En Chen2, Zach Heimer2, Roman Kubas2, Fwu-Shan Shieh2, Elena S. Kim4, Yuanjie Liu4, Daryl T. Y. Lau5, Ting-Tsung Chang6, Haitao Guo4, Zhili Wang2 and Ying-Hsiu Su1\*

**Authors’ affiliations:**

1 The Baruch S. Blumberg Research Institute, Doylestown, PA, 18902, USA

2 JBS Science, Inc., Doylestown, PA,18902, USA

3 Gilead Sciences, Inc, Foster City, CA, 94404, USA

4 Department of Microbiology and Immunology; Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA

5 Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA

6 Department of Internal Medicine, National Cheng Kung University Medical College, Center of infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan, Republic of China

**Corresponding Author:**

\*Ying-Hsiu Su, The Baruch S. Blumberg Research Institute, 3805 Old Easton Rd, Doylestown, PA, 18902; Tel: 215-489-4949; Fax: 215-489-4920; E-mail: Ying-hsiu.su@bblumberg.org.

Contents

[Supplementary Figures 3](#_Toc183801505)

[Supplemental Figure 1. iDNA Estimation Model Development. 3](#_Toc183801506)

[Supplemental Figure 2. iDNA sequence in SNU398 cell-line DNA. 4](#_Toc183801507)

[Supplemental Figure 3. iDNA sequences in Hep3B cell-line DNA. 5](#_Toc183801508)


[Supplemental Figure 4. HBV DNA and iDNA breakpoint coverage maps of tissue DNA from four CHB patients. 6](#_Toc183801509)

[Supplementary Table 7](#_Toc183801510)

[Supplemental Table 1. Junction qPCR primers for iDNA estimation model development. 7](#_Toc183801511)

[Supplemental Table 2. iDNA junction ratio in SNU398 and Hep3B cell-line DNA. 9](#_Toc183801512)

# Supplementary Figures

****

# Supplemental Figure 1. iDNA Estimation Model Development.

Development of a linear model for iDNA estimation by NGS reads for samples that have low viral load of <4 log IU/ml. This is under the assumption that there should only be limited viral replication in the low viral load group, thus the HBV DNA in infected liver should be either cccDNA or iDNA. In order to generate the linear model to estimate iDNA using NGS data, we identified 6 HBV-JS from low HBV viral load group that have abundances of at least 10% of total HBV-JS in that sample or can expand the applicable range (x-axis) of this model, to assess the model performance.

**A screenshot of a computer

Description automatically generated**

# Supplemental Figure 2. iDNA sequence in SNU398 cell-line DNA.


(A) IGV of HBV fragments from HBV-NGS. (B) iDNA structure. (C) iDNA sequence from sequence assembly.

**A black screen with white text

Description automatically generated**

# Supplemental Figure 3. iDNA sequences in Hep3B cell-line DNA.

(A) IGV of HBV fragments from PacBio long reads. (B) iDNA structures. (C) iDNA sequences from long read consensus.



# Supplemental Figure 4. HBV DNA and iDNA breakpoint coverage maps of tissue DNA from four CHB patients.

# Supplementary Table

# Supplemental Table 1. Junction qPCR primers for iDNA estimation model development.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient ID** | **% HBV coverage** | **Junction ID** | **Junction coordinates**  **[hg38, HBV]** | **Junction SR (% in total HBV-JS)** | **Junction Sequence (5'-3')** | **Forward primer (5'-3')** | **Reverse primer (5'-3')** | **qPCR AT conditions** |
| 55 | 100% | 55-1 | [Chr13:107773494, 94] | 84 (32.9%) | CAAAGCCTAAAAACGCATACTGTTGTTAAAAATAAGAGATCTTTGTAGAATAATACTTGGTTTTAGAAAAATTATTCAAAATACAGGAATAGAATTAGGACAAGAATAAGAAATCAGTCCGACTACTGCCTCTCACATATCGT | GATCTTTGTAGAATAATACTTGGTT | TATGTGAGAGGCAGTAGTCG | 60°C |
| 50 | 100% | 50-1 | [Chr8:5786566, 1829] | 125 (13.5%) | TAACTCCACAGTAGCTCCAAATTCTTTATAAGGGTCAATGTCCATGCCCCAAAGCCACCCAAGGCACAGCTTGGAGGCTTGAACAGTGGGACATGTACAAGAGATGATTAGGCAGAGCTGGGTGGCGTGGAGCATGGGATGAAGCAAGCAACACGAAGCTGTCATTCCCAGCCTCTGTGTGTCATTCTTAGATAATTTTGCCCCAGTACACTGCTGCATCTTCTCAACTGGACTT | CAGTGGGACATGTACAAGAGAT | TTGAGAAGATGCAGCAGTGTA |
| 50-2 | [Chr8:5786557, 1831] | 182 (19.6%) | AGAGTAACTCCACAGTAGCTCCAAATTCTTTATAAGGATCAATGTCCATGCCCCAAAGCCACCCAAGGCACAGCTTGGAGGCTTGAACAGTAGGACATGAACAAGAGATGATTAGGCAGGACTGCACTGGTCCTGCGAGCTCCCCTCCTGGCGCACAGGAGAGCAGAGGGGCCACCATTTGCCTGGCTGTCGGGCTGTCCCTGAAGAACTGCTTTAGTTTCTTCCTGTCGAGATTGC | GCTTGGAGGCTTGAACAGTA | CTAAAGCAGTTCTTCAGGGACA |
| 25 | 100% | 25-4 | [Chr4:77818365, 950] | 23 (5.79%) | GCATATAAAGGCATTAAGGCAGGATAGCCACATTGTGTAAAAGGGGCAGCAAAGCCCAAAAGACCCACAATTCTCTGACATACTTTCCAATCAATAGGTCTATTTACAGGCAGTTTTCACAAAATCCATCCAATCCCACAGGCCAGGAAAGCCAGTTTCCCTTTCTTCCTCAGCCCTTCCAAGAAAATGTTTGTCTAATTAAAAAAAAAAAAATCTTACNNACG | TAAGGCAGGATAGCCACATTG | GCTGAGGAAGAAAGGGAAACT |
| 43 | 100% | 43-1 | [Chr5:57298932, 1839] | 408 (21.0%) | CAAAAAAGAGAGTAACTCCACAGAAGCTCCAAATTCTTTATACGGGTCAATGTCCATGCCCCAAAGCCACCCAAGGCACAGCTTGGAGGCTTGAACAGTAGGACATGAACATGAGATGACAGAGCCCCTGTATGACAGTTGTTTAGAACAGAAACATGCTCTTTTTGCCTCTCCTCCAGCCACCACCCACTCCACTACCATGATCAGTAAGGTGGGAAGGAATCCAAAGGGCCATAG | TATACGGGTCAATGTCCATGC | CTTACTGATCATGGTAGTGGAGTG |
| 43-2 | [Chr5:57298966, 1867] | 389 (20.1%) | TATTAAAAAAGTTTAACACACCCTGATTAGTCTCTTTCCTTTTCTTCTCAGCCTCTCCAAAGAGAATCATCTCTTGACTGTCACTGCAATAGCCAAATTAAACCACAAATTAACCCACAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGCATGGACATTGACCCGTATAAAGAATTTGGAGCTTCTGTGGAGTTACTCTCTTTTTTGCCTTCTGACTTCTTTCCTTCT | CTCAGCCTCTCCAAAGAGAATC | AACTCCACAGAAGCTCCAAAT |
| SNU398 | 49% | S1 | [Chr19:35376685,448] | 1234 (59.1%); 1436 (60.7%) | ATAGAGGTTCCTTGAGCAGGAGTCGTGCAGGTCTTGCATGGTCCCGTGCTGTTTGATGTTCCTGGAAGTAGAGGACAAACGGGCAACATACCTTGGTAGTCCCAAGTTGCCCAGGCTGGTCTCGAACTCCTGATCACAAA | GCAACATACCTTGGTAGTCC | GATCAGGAGTTCGAGACCAG | 60°C |
| S2 | [Chr19: 35410237,1301] | 852 (40.8%); 923 (39%) | AAAAACCAAGTTGATGTGGCTCTGTTAAAATCAGACAAAATCAATGTTAAGGCAGAAAGAATTTTGAAAGTTTCAATTCACCAGGGAGACAGCAGCCGGTCTGGAGCAAAACTTATCGGGACTGACAACTCTGT | AAGTTTCAATTCACCAGGGAGACAG | AGTCCCGATAAGTTTTGCTCCA | 62°C |
| Hep3B | 75% | H1 | [Chr13:91169310,2056] | 784 (33.6%); 810 (36.2%) | ACACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCATTGCTCTCCTCACCATCATTGGTAGACAGAGAGTCTGATAGGAGTTGTTAGGAAACAGACAGAGAGAGCAAATATCTGGAAACCCT | CCTTAGAGTCTCCTGAGCATTG | TCCTATCAGACTCTCTGTCTACC | 55°C |
| H2 | [Chr3: 75917792,1793] | 698 (30%); 687 (30.7%) | GTGTGTTTAAGGACTGGGAGGAGCTGGGGCGGAGATTAGGTTACTGATCTTTGTATTAGGAGGCTTTAGGCCTAAATCACTGGTCATTAGAGAAATGCAAATCAAACCCACAATGACATACCATCTCACACCA | GATTTGCATTTCTCTAATGACCAGTG | CTTTGTATTAGGAGGCTGTAGGC | 62°C |

AT, denotes specific qPCR assay annealing Tm where each qPCR protocol is as follows “95°C, 5 min, 45 cycles (95°C, 10 s, AT °C, 10 s 72°C, 10 s)”

Note: underlines indicate HBV sequences.

# Supplemental Table 2. iDNA junction ratio in SNU398 and Hep3B cell-line DNA.

|  |  |  |  |
| --- | --- | --- | --- |
| Average Cq ± SD | **S1** | **S2** | **CG3** |
| SNU398 | 25.50 ± 0 | 25.19 ± 0.03 | 25.13 ± 0.01 |
| 0.81 (S1/S2 ratio)\* | |  |
| Average Cq ± SD | **H1** | **H2#** | **CG1** |
| Hep3B | 26.23 ± 0.153 | 26.04 ± 0.017 | 27.67 ± 0.007 |
| 0.876 (H1/H2 ratio\* | |  |

\*Calculated as described in the Methods using the formula: 2^(-ΔCp); #, Cq values were normalized by amplification efficiency between H1 and H2 qPCR assays.